Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

ADVANTAGE DIAGNOSTICS CLINICAL LABORATORY LLC

NPI: 1497486880 · EAST BRUNSWICK, NJ 08816 · Clinical Medical Laboratory · NPI assigned 06/17/2022

$234K
Total Medicaid Paid
10,046
Total Claims
5,128
Beneficiaries
9
Codes Billed
2022-06
First Month
2024-09
Last Month

Provider Details

Authorized OfficialGENKIN, POLINA (OWNER)
NPI Enumeration Date06/17/2022

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2022 9,846 $232K
2024 200 $2K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 3,294 1,652 $156K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 3,281 1,642 $52K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 3,271 1,647 $25K
87481 22 22 $1K
87641 22 22 $285.56
87640 22 22 $285.56
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 70 64 $99.42
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 39 32 $0.00
87150 25 25 $0.00